Nifty
Sensex
:
:
14617.85
48832.03
36.40 (0.25%)
28.35 (0.06%)

Pharmaceuticals & Drugs - Global

Rating :
54/99

BSE: 532296 | NSE: GLENMARK

571.90
16-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  539.95
  •  578.00
  •  525.65
  •  536.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  11468653
  •  64413.39
  •  578.00
  •  304.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,137.20
  • 16.87
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 19,894.59
  • 0.44%
  • 2.39

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.63%
  • 1.15%
  • 15.92%
  • FII
  • DII
  • Others
  • 25.84%
  • 8.56%
  • 1.90%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.69
  • 7.07
  • 5.45

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.11
  • 3.39
  • 1.00

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.53
  • 0.87
  • -1.17

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.55
  • 16.74
  • 15.55

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.78
  • 3.49
  • 2.37

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.81
  • 11.28
  • 9.64

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
2,786.76
2,735.56
1.87%
2,952.48
2,815.04
4.88%
2,344.79
2,322.88
0.94%
2,767.49
2,563.47
7.96%
Expenses
2,256.69
2,295.49
-1.69%
2,399.67
2,364.63
1.48%
1,866.72
1,980.97
-5.77%
2,301.80
2,199.34
4.66%
EBITDA
530.07
440.08
20.45%
552.81
450.41
22.73%
478.07
341.91
39.82%
465.69
364.13
27.89%
EBIDTM
19.02%
16.09%
18.72%
16.00%
20.39%
14.72%
14.01%
14.01%
Other Income
15.09
32.96
-54.22%
-31.88
80.83
-
58.51
1.67
3,403.59%
44.14
39.06
13.01%
Interest
95.41
96.06
-0.68%
80.63
89.77
-10.18%
93.74
93.02
0.77%
98.47
81.91
20.22%
Depreciation
115.20
106.00
8.68%
104.07
94.16
10.52%
113.22
90.73
24.79%
126.28
80.97
55.96%
PBT
347.97
270.98
28.41%
339.38
347.30
-2.28%
357.61
159.83
123.74%
317.96
240.31
32.31%
Tax
99.79
80.14
24.52%
105.38
91.76
14.84%
103.57
50.55
104.89%
97.65
78.65
24.16%
PAT
248.18
190.84
30.05%
233.99
255.54
-8.43%
254.04
109.28
132.47%
220.31
161.66
36.28%
PATM
8.91%
6.98%
7.93%
9.08%
10.83%
4.70%
7.11%
7.11%
EPS
8.80
6.76
30.18%
8.29
9.06
-8.50%
9.00
3.87
132.56%
28.29
28.29
0.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
10,851.52
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
Net Sales Growth
3.97%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
 
Cost Of Goods Sold
7,404.55
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
Gross Profit
3,446.97
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
GP Margin
31.76%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
Total Expenditure
8,824.88
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
Power & Fuel Cost
-
173.69
165.25
137.47
127.02
120.47
109.11
93.50
80.13
0.00
0.00
% Of Sales
-
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
Employee Cost
-
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
% Of Sales
-
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
Manufacturing Exp.
-
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
40.76
% Of Sales
-
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
General & Admin Exp.
-
1,168.32
891.10
526.29
1,022.89
491.20
253.29
859.67
678.94
1,331.99
854.82
% Of Sales
-
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
Selling & Distn. Exp.
-
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
% Of Sales
-
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
Miscellaneous Exp.
-
47.19
33.29
314.55
88.52
38.82
38.48
228.40
33.61
0.00
0.00
% Of Sales
-
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
EBITDA
2,026.64
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
EBITDA Margin
18.68%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
Other Income
85.86
159.60
208.14
91.40
37.37
20.00
6.88
11.48
10.75
18.17
144.41
Interest
368.25
377.32
334.58
285.57
237.32
178.88
190.15
188.59
160.01
146.57
160.46
Depreciation
458.77
417.17
325.90
301.88
264.37
234.28
300.41
216.79
127.01
97.88
94.68
PBT
1,362.92
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
Tax
406.39
320.11
375.64
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
Tax Rate
29.82%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
PAT
956.52
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
PAT before Minority Interest
956.52
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
Minority Interest
0.00
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
PAT Margin
8.81%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
PAT Growth
33.35%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
 
EPS
33.90
27.50
32.78
28.48
39.29
26.34
7.43
19.22
21.97
16.31
16.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
Share Capital
28.22
28.22
28.22
28.22
28.22
27.13
27.12
27.09
27.05
27.03
Total Reserves
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
Non-Current Liabilities
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
Unsecured Loans
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
14.58
6.90
Current Liabilities
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
Trade Payables
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
Other Current Liabilities
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
Short Term Borrowings
442.60
303.02
295.04
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
Short Term Provisions
555.91
484.11
432.46
262.95
134.03
216.78
259.95
33.22
10.63
11.62
Total Liabilities
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
Net Block
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
Gross Block
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
Accumulated Depreciation
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
Non Current Assets
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
Capital Work in Progress
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
145.70
Non Current Investment
24.59
29.66
14.66
15.69
17.20
17.12
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
123.97
94.36
119.78
98.94
69.99
468.16
33.39
36.52
0.00
0.00
Other Non Current Assets
26.49
15.80
0.56
0.13
0.16
0.27
20.33
22.00
33.23
30.92
Current Assets
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
Sundry Debtors
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
Cash & Bank
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
195.83
Other Current Assets
1,147.78
765.22
810.78
683.39
986.77
774.38
872.81
635.91
593.95
465.11
Short Term Loans & Adv.
544.48
547.18
580.83
590.22
594.89
742.94
768.44
540.03
518.90
322.39
Net Current Assets
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
Total Assets
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
930.58
PBT
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
Adjustment
636.23
329.83
571.28
726.56
391.03
522.76
709.78
342.45
484.05
189.65
Changes in Working Capital
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
Cash after chg. in Working capital
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
Net Fixed Assets
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
Net Investments
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
Others
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
Cash from Financing Activity
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
Net Cash Inflow / Outflow
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
165.21
127.70
Opening Cash & Equivalents
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
103.58
Closing Cash & Equivalent
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
214.65
198.27
182.62
159.16
128.59
65.74
109.99
102.01
88.77
75.38
ROA
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
ROE
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
ROCE
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
Fixed Asset Turnover
1.44
1.66
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
Receivable days
78.95
83.73
94.95
97.29
119.39
125.97
115.37
104.99
107.78
136.71
Inventory Days
75.25
79.22
83.59
73.65
67.68
59.42
53.99
59.39
72.38
93.78
Payable days
98.44
97.43
96.28
101.59
117.03
95.22
83.15
68.48
108.47
106.73
Cash Conversion Cycle
55.77
65.53
82.26
69.35
70.04
90.17
86.21
95.91
71.69
123.76
Total Debt/Equity
0.80
0.80
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
Interest Cover
3.90
4.89
4.92
7.28
6.84
3.86
4.70
5.62
4.33
4.00

News Update:


  • Glenmark Pharmaceuticals’ arm files draft red herring prospectus with SEBI for IPO
    17th Apr 2021, 12:18 PM

    The IPO will be subject to market conditions, receipt of applicable approvals and other considerations

    Read More
  • Glenmark Pharma gets USFDA’s nod for Chlorpromazine Hydrochloride Tablets
    24th Mar 2021, 09:36 AM

    The company’s current portfolio consists of 171 products authorized for distribution in the U.S. marketplace

    Read More
  • Glenmark Pharmaceuticals gets $40 million COVID credit line from IFC
    23rd Mar 2021, 15:18 PM

    The loan to Glenmark will help it increase the availability of affordable, quality medicines in the country as well in other countries, including treatment for the pandemic

    Read More
  • Glenmark Pharma gets USFDA’s approval for Diltiazem Hydrochloride Extended-Release Capsules
    23rd Mar 2021, 09:59 AM

    Glenmark’s current portfolio consists of 170 products authorized for distribution in the U.S. marketplace and 42 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark Pharma’s arm inks pact with Bausch Health to commercialize RYALTRIS nasal spray in Canada
    22nd Mar 2021, 10:25 AM

    Glenmark will be responsible for regulatory approvals and supply of RYALTRIS for the Canadian market

    Read More
  • Glenmark signs Rohit Sharma as brand ambassador of Candid Powder
    5th Mar 2021, 09:45 AM

    The company’s Candid Dusting Powder is an expert skin solution to four key skin problems: redness, irritation, sweat rash and fungal infections

    Read More
  • Glenmark Pharma wins ‘India Pharma Innovation of the Year’ Award
    25th Feb 2021, 14:38 PM

    The award recognizes Glenmark’s multiple patents and innovations over the last three years, in its core therapy areas of Dermatology, Respiratory and Oncology

    Read More
  • Glenmark Pharmaceuticals’ arm receives approval for Ryaltris Nasal Spray
    22nd Feb 2021, 08:59 AM

    This paves the way for commercialization of Ryaltris in Russia which is expected to be made available to patients in the country in Q1 FY 2021-22

    Read More
  • Glenmark Pharmaceuticals launches SUTIB to treat kidney cancer in India
    16th Feb 2021, 09:33 AM

    Sunitinib is an oral multi-kinase inhibitor, works by blocking several enzymes that promote cell growth

    Read More
  • Glenmark Pharma reports 30% rise in Q3 consolidated net profit
    13th Feb 2021, 09:59 AM

    Total consolidated income of the company increased by 1.20% at Rs 2,801.85 crore for Q3FY21

    Read More
  • Glenmark Pharmaceuticals gets final approval for Clindamycin Phosphate Gel from USFDA
    11th Feb 2021, 11:37 AM

    Sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million

    Read More
  • Glenmark gets USFDA’s nod for Topiramate Extended-Release Capsules
    3rd Feb 2021, 09:58 AM

    The Qudexy XR Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg market achieved annual sales of approximately $120.8 million

    Read More
  • Glenmark gets USFDA’s nod for Amphetamine Sulfate Tablets
    28th Jan 2021, 09:52 AM

    Glenmark’s current portfolio consists of 168 products authorized for distribution in the U.S. marketplace and 43 ANDA’s pending approval with the USFDA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.